ILLINOIS PRESCRIPTION MONITORING PROGRAM

Advisory Committee Meeting

June 21st, 2017

12:00 - 1:30 PM

ROLL CALL

- Roll Call of Voting Members
- Meeting Minutes from March 15, 2017 Meeting

OPEN ISSUES

- Should Coroners/Medical Examiners have access to ILPMP data?
- ILPMP Unsolicited letters to identified high risk patients.
- Peer review meeting summary.

SAMPLE UNSOLICITED PATIENT LETTER

Dear patient's name:

This letter of concern to you comes from the members of the Illinois Prescription Monitoring Program. This is an electronic statewide monitoring program of all prescriptions for controlled substances in Illinois. These are prescriptions for medications with the potential for abuse, misuse, addiction, over dosage, and accidental death.

You are receiving this letter because of our concerns for your safety. You have received .. prescriptions for .. different controlled substances over the previous .. months. We are fully aware that there may be legitimate health reasons for each prescription. However, it is our responsibility to contact you and your providers to ensure that there is coordination of care if, in fact, there is a legitimate medical need. These medications alone or in combination with each other have significant risks and awareness of all of the patient's prescriptions is paramount to ensuring safe

It is also our responsibility to investigate this situation to the extent of sending these letters to both you and your providers to verify that you are not developing an unhealthy relationship with the medication. The risk of developing a substance abuse disorder with these controlled substances has been estimated to be as high as 20% of individuals exposed to them for medical care. Such a condition is associated with compulsive rather than controlled use of these medications and a growing psychological dependence on the medication. If this is a concern, please seek help as soon as possible with a substance abuse center, an addictionologist, or at least your primary care provider.

TECHNICAL UPDATES

- Update on Automated Connections
- CDC Meeting

CURRENT LEGISLATION

• Legislative Update

oNew Business?



THE NATIONAL INTERVENTIONAL PAIN MANAGEMENT- QUALIFIED CLINICAL DATA REGISTRY (NIPM-QCDR)

- The NIPM-QCDR has been approved for 2017
- The NIPM-QCDR fulfils the demands of The Merit-based Incentive Payment System under the CMS Quality Payment Program
- American Society of Interventional Pain Physicians (ASIPP) states NIPM-QCDR will capture and analyze data for physicians
- Physicians will enhance their performance to improve patient outcomes and optimize future reimbursements, if participating in NIPM-QCDR

AMID GROWING HEALTH CONCERNS, FDA RECOMMENDS OPIOID PULED FROM MARKET

Illinois Prescription Monitoring Program

OPANA ER

• The FDA recently removed extended-release oxymorphone hydrochloride (Opana ER), from the market due to concern that the benefits of the drug may no longer outweigh its risks.

OPIOID REMOVAL CAUSED BY

- Concerns for abuse
- Serious disease outbreak
- Dangerous unintended consequences
- Potential for misuse

OPIOID ASSOCIATED WITH THE FOLLOWING

- Opioid overdose
- Outbreaks of HIV
- Hepatitis C virus
- Blood disorder thrombotic microangiopathy

NEEDS TO PRIORITIZE PRESCRIBING OPIOIDS

- Managed care (payers)
- Centers for Medicare
- Medicaid services

BEYOND OPIOIDS: SURGEONS EXPLORE NEW APPROACHES TO PAIN CONTROL

Illinois Prescription Monitoring Program

TECHNIQUES SURGEONS ARE WORKING WITH PAIN SPECIALIST AND ANESTHESIOLOGISTS

- More multimodal pain control
- Nonnarcotic used with or without opioids
- Cognitive-behavioral therapy
- Avoidance of opioids in some opioid-native patients

PAIN TREATMENT EMPHASIZES

- Comprehensive care
- Physical therapy
- Pain psychology
- Self management strategies

Vulnerable to Chronic Opioid Use

- Men and patients over 50 years of age
- History of drug abuse
- History of alcohol abuse
- History of depression
- History of benzodiazepine

CONSEQUENCES OF OPIOIDS

- Sharing and selling of opioids
- Diverted to unintended users
- Putting patients at risk for chronic opioid use

Biomarkers Could Help Select Best Candidates for SCS

Illinois Prescription Monitoring Program

Spinal Cord Stimulation (SCS)

- Researchers wish to develop biomarkers to benefit chronic neuropathic pain
- Biomarkers could streamline patients' experience
- Greatly reduce medical costs

SCS Used to Improve

- Failed back surgery syndrome
- Other chronic pain syndromes
- Physical function
- Quality of life

Challenges with SCS

- Sources of inflammation
- Inflammatory process could interfere with cytokine biomarkers
- Developing funding

Wanting End Result

- Construct a blood test that would predict good outcomes
- Find better outcomes over the long term effects
- In the near future this idea would lead to newer ideas that would benefit the patients

Adjournment

Next Meeting: September 20, 2017

Motion to Adjourn.